



A focus on childhood pneumonia in Ethiopia and Tanzania

Mr. Meles Solomon, MoH, Ethiopia Dr. Felix Bundala, MoH, Tanzania Samantha Durdock, R4D, USA Nelsha Haji, R4D, Tanzania

June 6, 2023

Theme

PHC

ADDRESSING

STRENGTHENING

INEQUITIES

THROUGH



ACCELERATING PROGRESS TOWARDS THE 2030 SDGS - REDUCING INEQUITIES IN CHILD HEALTH CONFERENCE | JUNE 6-7, 2023

Introducing our speakers

Facilitator



Nelsha Haji Senior Program Officer, R4D, Tanzania

Presenters and Panelists



Meles Solomon National Newborn and Child Health Program Desk Head, MoH, Ethiopia



Dr. Felix Bundala Assistant Director of Newborn and Child Health, MoH Tanzania



Samantha Durdock Senior Program Officer, R4D, USA



Results for Development is a mission-driven global nonprofit working to improve access to high-quality, affordable health care, improve educational opportunities for children and reduce malnutrition.






Poll: What is the number one cause of death for children under 5 in the African region?





2. WHO: Maternal, Newborn, Child and Adolescent Health & Ageing, Data Portal

ARIs, most commonly pneumonia, are the highest contributor to CU5 mortality followed by malaria and diarrhea; this is true globally and within the African region...






Sources:

2. WHO: Maternal, Newborn, Child and Adolescent Health & Ageing, Data Portal

ARIs, most commonly pneumonia, are the highest contributor to CU5 mortality followed by malaria and diarrhea; this is true globally and within the African region...

....yet over a 10-year period, pneumonia only received 7% (\$7.1 billion) of total global donor funding given to malaria and HIV/AIDS combined (\$108.7 billion)






Sources:

UNICEF (2019)

WHO: Maternal, Newborn, Child and Adolescent Health & Ageing, Data Portal

ARIs, most commonly pneumonia, are the highest contributor to CU5 mortality followed by malaria and diarrhea; this is true globally and within the African region...


....yet over a 10-year period, pneumonia only received 7% (\$7.1 billion) of total global donor funding given to malaria and HIV/AIDS combined (\$108.7 billion)



While the existence of amox DT, a cost-effective, WHO-recommended antibiotic is available, access to this life-saving commodity is still not wide-spread



Using a holistic market shaping approach, the Governments of Ethiopia and Tanzania have focused on scaling up access to amoxicillin dispersible tablets (amox DT) to help address inequity challenges related to treatment availability with R4D support



A holistic market shaping approach focused on sustainable financing in addition to alleviating supply, demand and regulatory barriers has led to 90%+ number of health facilities with amox DT available and approx. 75% reduction in amox DT stockouts across both countries




Ethiopia



Tanzania



ources: CHAI, 2019 GHSC-PSM, 2021 Tanzania health facility surveys A holistic market shaping approach focused on sustainable financing in addition to alleviating supply, demand and regulatory barriers has led to 90%+ number of health facilities with amox DT available and approx. 75% reduction in amox DT stockouts across both countries





48%

% of facilities with amox DT available³




Tanzania health facility surveys

Sources:

3

CHAI, 2019 GHSC-PSM, 2021 A holistic market shaping approach focused on sustainable financing in addition to alleviating supply, demand and regulatory barriers has led to 90%+ number of health facilities with amox DT available and approx. 75% reduction in amox DT stockouts across both countries







GoE and GoT, with R4D TA, first co-analyzed key market barriers impeding access, and then co-developed TA activities to drive solutions to create a more enabling market environment for amox DT scale-up

Market Dimension	Market Barriers Identified in 2014-2015
Supply	 0-1 registered suppliers in both countries 0 quality assured suppliers registered
Demand	 Inadequate forecast and quantification methodology for amox DT leading to inaccurate demand estimations Amox DT procurement not led by national procurement agency
Regulatory	 Misaligned policies related to Amox DT use (across treatment guidelines, essential medicine lists)
Financing	 Amox DT facing funding cliff across both countries No plan for sustainable financing in place



GoE and GoT, with R4D TA, first co-analyzed key market barriers impeding access, and then co-developed TA activities to drive solutions to create a more enabling market environment for amox DT scale-up


Market Dimension	Market Barriers Identified (2014-2015)	TA Activities and Impact (2016-2023)
Supply	 0-1 registered suppliers in both countries 0 quality assured suppliers registered 	 Increased market transparency & presented business cases to quality assured amox DT manufacturers to encourage registration in country ET: From 0 registered suppliers to 8 registered suppliers, 4 of which are high quality* TZ: From 1 registered supplier to 8 registered suppliers, 3 of which are high quality* * High quality supplier = at minimum, supplier has WHO-GMP certification
Demand	 Inadequate forecast and quantification methodology for amox DT leading to inaccurate demand estimations Amox DT procurement not led by national procurement agency 	 Analyzed and triangulated consumption, morbidity and seasonality data to inform and strengthen Amox DT quantification methodology while strengthening procurement and supply planning processes at national procurement agency (NPA) level ET: Supported GoE to lead exercises related to forecasting, supply planning, resource tracking; strengthened quantification methodology TZ: Strengthened quantification methodology, increased forecasted demand by 177% in the first year in TZ; transitioned amox DT procurement to NPA from external agency
Regulatory	 Misaligned policies related to Amox DT use (across treatment guidelines, essential medicine Hists) 	Advocated for and supported policy revisions to enable a fully aligned policy environment in both countries
Financing	 Amox DT facing funding cliff across both countries No plan for sustainable financing in place 	Catalyzed time-limited donor financing to avert immediate funding cliff and supported govt's to identify alternate domestic funding sources for sustainable financing ET: GoE has mobilized 42% of the funding needed between 2016 & 2022 from various domestic resources TZ: Amox DT to be fully financed by government domestic resource mobilization by the end of 2023 Focus of the discussion

WIZARA YA

While holistic TA is needed to address all market barriers to drive impact, sustainable financing was key to mobilize domestic resources and avoid another funding cliff



GoE commitment on mobilization and allocation from Sustainable Development Goal-pooled fund for procurement of amox DT increase significantly to the extent that, for 2020-2021 budget year, all funding for amox DT came from this pooled fund and domestically mobilized revolving drug fund




Path to sustainable financing in Ethiopia

Supported GoE to explore and establish domestic resource options for commodity financing with R4D resource mobilization and financing TA:

- Making amox DT part of revolving drug fund (RDF) which enables health facilities to use their own budget to procure the medicine
- Increased allocation of MOH mobilized
 SDG-PF for amox DT procurement; which is a fund used to fill procurement funding gaps due to budget shortfall
- Supporting establishment of health pool fund that consists of domestically mobilized resources that can used for commodity procurement and help ensure access to critical health services particularly in times of financial constraint, emergencies, etc.

The GoT commitment to amox DT financing demonstrates incremental increases in investment, despite the disruption of Covid-19 in 2020; the GoT, through it's domestic resource mobilization efforts and health facility budgets, the GoT will take on 100% of amox DT In by the end of 2023.



Donor Financing (Actual)

GoT Resource Mobilization (Planned)



Path to sustainable financing in Tanzania

Supported the GoT to prioritize sustainable financing for amox DT and explore sustainable financing options through R4D resource mobilization and financing TA:

- **Established MoU** with the government that clearly articulated sustainable financing goals
- Development of **co-financing agreement**
- **Flexibility and adaptability** on co-financing terms in the midst of a pandemic
- Empowering GoT to lead resource mobilization and identify domestic resource fund options for Amox DT
- Development and implementation of plan to transition amox DT to GoT health facility budgets

Panel Discussion

